HBx Mediated Increase of DDX17 Contributes to HBV-Related Hepatocellular Carcinoma Tumorigenesis

Mei-Ling Dong†, Xu Wen†, Xin He, Ji-Hua Ren, Hai-Bo Yu, Yi-Ping Qin, Zhen Yang, Min-Li Yang, Chong-Yang Zhou, Hui Zhang, Sheng-Tao Cheng* and Juan Chen*

Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, Chongqing Medical University, Chongqing, China

HBV is strongly associated with HCC development and DEAD-box RNA helicase 17 (DDX17) is a very important member of the DEAD box family that plays key roles in HCC development by promoting cancer metastasis. However, the important role of DDX17 in the pathogenesis of HBV-related HCC remains unclear. In this study, we investigated the role of DDX17 in the replication of HBV and the development of HBV-associated HCC. Based on data from the GEO database and HBV-infected cells, we found that DDX17 was upregulated by the HBV viral protein X (HBx). Mechanistically, increased DDX17 expression promoted HBV replication and transcription by upregulating ZWINT. Further study showed that DDX17 could promote HBx-mediated HCC metastasis. Finally, the promotive effect of DDX17 on HBV and HBV-related HCC was confirmed in vivo. In summary, the results revealed the novel role of DDX17 in the replication of HBV and the metastasis of HBV-associated HCC.

Keywords: DDX17, HBx, HCC, metastasis, ZWINT

INTRODUCTION

Liver cancer remains one of the most important causes of cancer death worldwide. Recently, approximately 700,000 deaths were attributed to liver cancer worldwide (1). Hepatocellular carcinoma (HCC) is the seventh most common cancer in women, the fifth in men (2), and the third leading cause of cancer-related death (3). The risk factors for HCC include autoimmune hepatitis, alcohol abuse, diabetes mellitus, and chronic hepatitis B virus (HBV) infection (4–9). Although operation and antiviral therapies have made significant progress, the median survival of patients with HCC is limited to approximately 6 to 20 months due to metastasis following diagnosis (10). Therefore, elucidation of the mechanism underlying HBV-related HCC metastasis will improve the prognosis of patients with HCC.

Abbreviations: HBV, hepatitis B virus; HBx, hepatitis B viral X protein; DDX17, DEAD-box RNA helicase 17; HCC, hepatocellular carcinoma; ZWINT, ZW10 interacting kinetochore protein; HBsAg, hepatitis B surface antigen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NTCP, Na+/taurocholate cotransporting polypeptide; FBS, fetal bovine serum; AAV, adeno-associated virus; WT, wild-type; Co-IP, co-immunoprecipitation.
DEAD-box proteins, including 38 members in humans, 25 in yeast, and 9 in bacteria are very important members of the ATP-dependent RNA helicase families (11). They are generally essential components of large multiprotein complexes and play roles in RNA metabolism (12, 13). Recent studies have shown that DEAD-box family members play central roles in a variety of cancers and have different mechanisms (14–17). In particular, DEAD-box RNA helicase 17 (DDX17) has attracted substantial attention in cancer research because of its vital biological functions in tumorigenesis, proliferation, and especially, metastasis. The alteration of DDX17 activity reportedly affects pre-mRNA splicing, which is linked to pancreatic ductal adenocarcinoma metastasis and a malignant phenotype (18). A study on uveal melanoma found differential expression of DDX17 in clear-cell renal cell carcinoma (ccRCC) specimens suggests that DDX17 plays a key role in ccRCC metastasis (19).

In addition, our previous study found that DDX17 promotes HCC metastasis by regulating the alternative splicing of PXN-AS1 (20). Moreover, an increasing number of studies suggest that the DEAD-box family also plays a role in infection with viruses, including rift valley fever virus (RVFV), dengue virus (DENV), influenza A virus (IVA), and human immunodeficiency virus type 1 (HIV-1) (21–24). Considering that HBV infection, and especially the HBV viral protein X (HBx), is closely related to the occurrence, development, and metastasis of HCC (25–28). Debora Salerno and his colleagues showed that in infected hepatocytes, HBx can bind the promoter region of DLEU2 to enhance DLEU2 transcription, induce the accumulation of DLEU2 RNA species and promote the development of HCC (29). Moreover, another study reported that HBx enhances autophagy in HepG2 cells through the PI3K-Akt-mTOR pathway to regulate HCC and potentially promotes cancer metastasis (30). In addition, studies on HCC have suggested that HBx can regulate cancer stem cells to stimulate the proliferation and metastasis of HCC (31). Briefly, HBx functions as an oncogene in the occurrence, development, and metastasis of HCC and we, therefore, wanted to investigate whether DDX17 functions as a bridge between HBV with HCC and regulates HBV-related HCC together with HBx.

In this study, we investigated the role of DDX17 in HBV replication and discovered that DDX17 significantly promoted HBV replication by elevating the expression of ZWINT. Furthermore, we found that DDX17 affected the viral protein HBx to thereby regulate HBV-related HCC metastasis, indicating its great potential as a therapeutic target for HBV and HCC.

**Materials and Methods**

**PLASMIDS, ANTIBODIES AND REAGENTS**

The plasmid expressing DDX17 was obtained from Addgene (#19876). The ZWINT expression plasmid was successfully constructed by inserting full-length ZWINT into pcDNA3.1. Plasmids expressing different HBV viral proteins (HBc, preCore/core protein; HBs, S protein; HBx, X protein; and HBp, Pol protein) were constructed by inserting the full-length HBc, HBs and Pol sequences into pcDNA3.1, which has a Flag tag at the C-terminus. Plasmid pcH9/3091, containing a 1.1-mer HBV genome, was obtained from Prof. Lin Lan (The Army Medical University, Chongqing, China). An HBx-deleted HBV plasmid (HBV-ΔHBx) was obtained by introducing a stop codon at the beginning of the HBx gene based on pcH9/3091, thought to be wild-type HBV (HBV WT).

Short hairpin RNAs targeting DDX17 (shDDX17-1 and shDDX17-2) and a nontargeting shRNA (shCont) were obtained from Shanghai Genechem Company Limited (Shanghai, China), and the target shRNA sequences are provided in Supplementary Table 1. Short interfering RNAs (siRNAs) targeting ZWINT (siZWINT-1 and siZWINT-2) and a nontargeting siRNA (siCont) were obtained from Tsinge Biotechnology Company Limited (Beijing, China).

Rabbit anti-DDX17 (19910-1-AP), rabbit anti-ZWINT (12282-2-AP), rabbit anti-THBS1 (18304-1-AP) and rabbit anti-KIF23 (28587-1-AP) antibodies were obtained from Proteintech (Chicago, USA). The rabbit anti-Flag (#14793S) antibody was purchased from Cell Signaling Technology (Boston, USA), and the mouse anti-HBc was kindly provided by Dr. XueFei Cai (Chongqing Medical University, China). The rabbit anti-SLA2 (27794-1) antibody was purchased from Signalway Antibody (California, USA), and the mouse anti-GAPDH (MB001) antibody was purchased from Bioworld Technology (USA).

Doxorubicin was purchased from Solarbio (ID0670, Beijing, China), and G418 was purchased from BioFroxx (1150GR001, Germany).

**Quantitative Reverse Transcription PCR (qRT–PCR)**

Total RNA was extracted from cells and tissues using TRNzol (DP424, TIANGEN, Beijing, China) and reverse transcribed into cDNA using a Prime Script qRT–PCR kit (Bio–Rad, KR116-02, Bio–Rad, California, USA). The cDNA was amplified by qRT–PCR with Fast Start Universal SYBR Green Master and the relative levels...
of viral RNA and mRNA were determined by the $2^{\Delta\Delta CT}$ method; beta-actin served as the internal control. The primer sequences used in this study are shown in Supplementary Table 2.

**HBV DNA Extraction and Quantitative PCR**

Equal numbers of cells were lysed with 500 µL of lysis buffer at 37°C for 30 min. After centrifugation, the supernatant was added to a new 1.5 ml tube and incubated with 4 µL of DNase I and 5 µL of 1 M MgCl$_2$ at 37°C for 4 hours. After precipitation with 35% PEG8000, proteinase K was added to the tube and incubated with HBV DNA at 45°C overnight. Then, HBV DNA was extracted with phenol chloroform, washed with 70% ethanol, and dissolved in H$_2$O. Absolute quantification of the extracted HBV DNA was performed by using Fast Start Universal SYBR Green Master Mix (06924204001, Roche, Mannheim, Germany). The primer sequences are listed in Supplementary Table 2.

**Southern Blot**

HBV DNA was separated on 0.9% agarose gels and transferred onto nylon membranes (11417240001, Roche, Mannheim, Germany). After fixation by UV crosslinking and prehybridization, the membranes containing HBV DNA were hybridized with a digoxigenin-labelled HBV-specific probe overnight at 42°C and then washed with different concentrations of SSC containing 0.1% SDS. The membranes were incubated in a blocking solution at 37°C for 30 min and then incubated with an anti-Dig antibody at 37°C for 30 min. The signal was observed by exposure to an X-ray film.

**Northern Blot**

To analyze the total RNA extracted by TRNzol reagent, the DIG Northern Starter Kit (12039672910, Roche, Mannheim, Germany) was used according to the manufacturer’s protocol. Briefly, the total RNA extracted from cells was separated by 1.4% formaldehyde-agarose gel electrophoresis and washed with 20×SSC for 15 min at room temperature. Then, the RNA samples were transferred onto nylon membranes and fixed by UV crosslinking. The membranes were hybridized with a DIG-labelled HBV RNA probe overnight at 68°C and then washed with different concentrations of SSC containing 0.1% SDS. After incubation in blocking solution at 37°C for 30 min, the membranes were incubated with an anti-digoxin antibody at 37°C for 30 min. The signal was detected by using X-ray film, and 28S and 18S RNA served as internal controls.

**ELISA**

The secretion level of HBV surface antigen (HBsAg) in the cell culture medium was measured by a commercial ELISA kit (KHB, China) according to the manufacturer’s protocol. The cell culture medium was collected and centrifuged at 2,000 g for 3 min to remove the cell debris. Then, 75 µL of each sample was subjected to ELISA, and the absorbance at 450 nm was measured. Negative and positive controls were included with samples.

**Western Blot**

Cells were collected and subjected to total protein extraction by using RIPA lysis buffer containing protease inhibitors (04693159001, Roche, Mannheim, Germany). The protein concentration was determined by the BCA protein assay (1859078, Roche, Mannheim, Germany), and 30 µg of protein was denatured for 10 min at 95°C.

After separation by SDS–PAGE, the proteins were transferred onto polyvinylidene fluoride membranes (IPVH00010, GE Healthcare, Buckinghamshire, UK). After blocking with 5% nonfat milk for 2 hours, the membranes were incubated with relevant primary antibodies (anti-DDX17 protein 1:2000; anti-ZWINT protein 1:1000; anti-Flag 1:3000, anti-HBc 1:1000, anti-THBS1 1:3000, anti-KIF23 1:3000, anti-SLA2 1:3000, anti-GAPDH 1:5000) overnight at 4°C and then with the appropriate secondary antibody. The blots were visualized by ECL. Western blot reagents (WBKLS0500, Millipore. Massachusetts, USA), and GAPDH served as an internal control.

**Coimmunoprecipitation**

Cells were lysed with RIPA lysis (containing protease inhibitor) at 4°C for 20 min. After centrifugation at 16,000 g for 5 min at 4°C, the protein concentration was determined by the BCA assay (1859078, Roche, Mannheim, Germany). Lysates containing 600 µg of total protein were precleared with protein A/G magnetic beads (LSKMAgg10, Merck Millipore, Darmstadt, Germany) for 1 hour at 4°C. Next, the protein complex was incubated with the relevant primary antibody overnight at 4°C. The next day, after washing with PBS/0.1% Triton-100 three times, the protein A/G magnetic beads were added to the complex lysates and rotated for 2 hours at room temperature. Finally, the protein-antibody-bead complexes were eluted with 3× SDS loading buffer and subjected to Western blotting.

**Virus Collection and Infection**

HBV virion particles were obtained from the medium of HepAD38 cells. Briefly, the supernatants of HepAD38 cells were collected and then mixed with 4% PEG8000. The samples were then rotated gently at 4°C and dissolved overnight. The complexes were centrifuged at 4,000 rpm for 30 min at 4°C to collect HBV particles. The pellet was resuspended in Opti-MEM (Gibco) at a 100-fold concentration, and the viral titre was quantified by measuring HBV DNA by qPCR. For infection, cells in collagen-coated wells were infected with HBV particles diluted in William’s medium supplemented with 10% FBS, 2 mM sodium pyruvate, 200 µM L-glutamine, 2.5% dimethyl sulfoxide (DMSO), 4% PEG8000 and 1% P/S. HepG2-NTCP cells were infected with a total of 1,000 genome equivalents/cell of HBV particles in 4% PEG8000 for 24 hours and then washed twice with PBS before use in further experiments.

**In Vitro Assays of Transwell Migration**

Transwell chambers (24-well plate, 8 µm pores; cat# 356234, BD Biosciences) were used to assess the migration abilities of cells. Briefly, 2×10$^5$ HCC cells were resuspended in DMEM and seeded into the upper chamber and medium containing 10% FBS was added to the lower chamber. The cells were further cultured at 37°C/5% CO$_2$. Then, the migrated cells were fixed with 95% methanol and the cells in the upper chamber were scraped with a cotton swab, while those in the lower chamber were stained with 0.1% crystal violet dye. The number of migrated cells was counted under an inverted microscope.
Immunohistochemistry

The liver tissues of mice were fixed with formalin and embedded in paraffin. After deparaffinization in xylene, the sectioned tissues were microwaved and heated in sodium citrate buffer (10 mmol/L, pH 6.0). Then, the specimens were incubated with the indicated primary antibodies at 4°C overnight. Following counterstaining with the appropriated secondary antibody for 30 min, diaminobenzidine (DAB) staining was used to detect tissue immunoreactivity (Dako, Carpinteria, CA). Haematoxylin was used for counterstaining.

Construction of a Mouse Model of HBV Infection Using HBV Recombinant (r)cccDNA

C57BL/6 mice were purchased from the Laboratory Animal Center of Chongqing Medical University (Chongqing, China) and fed under pathogen-free conditions. Four micrograms of prcccDNA and four micrograms of Cre were diluted to 8% of the mouse body weight with PBS and then hydrodynamically injected into the mice via their tail vein within 5 to 8 s. After one week, the mice were randomly assigned to either the negative group (shCont, 2E+11 v.g/mL, n=8) or the treatment group (shDDX17, 2E+11 v.g/mL, n=8) and sacrificed at the indicated time points. Serum was collected every four days and stored at -80°C for further study. Liver tissues were collected for intrahepatic HBV RNA and HBV DNA detection. All animal studies conformed to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and were approved by the Laboratory Animal Center of Chongqing Medical University.

Clinical Samples

With informed consent, human HCC liver tissues were collected from 24 patients at The First Affiliated Hospital of Chongqing Medical University. All patients who provided liver tissues were diagnosed with HBV-related HCC and were HBsAg-positive. Metastasis was observed in 12 of the 24 patients. All tissues were frozen immediately upon resection and stored in liquid nitrogen for further investigation. This study was approved by The Clinical Research Ethics Committee of Chongqing Medical University.

Statistical Analysis

The results are expressed as the mean ± SD from at least three independent experiments. Statistical analyses were performed using either the Mann–Whitney U test or one-way ANOVA. P < 0.05 was considered significant (*P < 0.05, **P < 0.01). All statistical analyses were conducted using GraphPad Prism 8 (GraphPad) software (GraphPad Software, Inc., La Jolla, CA).

RESULTS

HBV Promotes DDX17 Expression and May Be Involved in HCC Metastasis

To explore the molecular mechanisms underlying HBV-related HCC metastasis, we analyzed the differentially expressed genes (DEGs) in the GSE83148 (comprising 122 HBV-infected liver tissues and 6 normal liver tissues) and GSE38941 (comprising 17 HBV-associated acute liver failure tissues and 10 normal liver tissues) GEO datasets. The 2 datasets were available on the GeneCloud of Biotechnology Information (GCBI) bioinformatics analysis platform and the DEGs were identified by using the GEO2R online analysis tool (log2FC>0.585, adjusted p <0.05). GSE83148 contained a total of 5,185 DEGs, including 4,646 upregulated and 539 downregulated genes, whereas GSE38941 contained 7,430 DEGs, including 4,224 upregulated and 3,206 downregulated genes (Figure 1A). As shown in Figure 1B, 2,945 DEGs (fold change value >2) were co-expressed in these two datasets (Figure 1B). To further analyze the functional roles of the co-expressed DEGs in the progression of HBV infection, the 2,945 genes were subjected to pathway analysis. Notably, 14 genes were enriched in epithelial to mesenchymal transition-related pathways (Figures 1C, D), indicating their potential involvement in HBV-mediated tumor metastasis. The expression levels of the 14 co-expressed genes (excluding FGFR1) were upregulated in both GSE83148 and GSE38941 (Figure 1E). Then, the effect of HBV infection on the expression levels of these 13 upregulated genes was further investigated in HBV-infected HepG2-NTCP cells, revealing that DDX17 expression was obviously increased (Figure 1F).

To further investigate the association between HBV infection and DDX17, the effect of HBV infection on DDX17 expression was first analyzed in HBV-infected HepG2-NTCP cells. Based on real-time PCR and Western blot analyses, both the mRNA and protein levels of DDX17 were upregulated in HBV-infected HepG2-NTCP cells on the indicated day after infection (Figures 2A, B). In addition, HepG2-NTCP cells were infected with increasing HBV particles at increasing MOIs (100, 250, 500, 1000 and 2000 virion genome equivalents/cell), and both the mRNA and protein levels of DDX17 were examined. As expected, the HBV-induced increase in DDX17 expression was dependent on the dose of the HBV particles (Figures 2C, D). Similar results were observed in HepG2-NTCP cells infected with HBV at a series of MOIs by immunofluorescence analysis (Figure 2E). Collectively, these data suggested that HBV upregulated the expression of DDX17.

The Viral Protein HBx Is Responsible for DDX17 Upregulation

Although our data showed that DDX17 expression was upregulated by HBV, the underlying mechanism is not known. To further investigate this, the effects of viral proteins (HBx, HBc, HBs, HBp) on DDX17 expression were first determined. Plasmids expressing the different HBV viral proteins were transfected into HepG2 or Huh-7 cells, and the DDX17 expression levels were examined by real-time PCR and Western blot. Fortunately, DDX17 expression was obviously increased in cells expressing HBx but not in those expressing the other HBV proteins (Figures 3A, B). To further elucidate whether HBx mediates the impact of HBV on DDX17 expression, we generated an HBx-deficient virus (HBVΔHBx) in which the expression of the X gene was abrogated. Decreased
levels of DDX17 were observed in cells infected with HBV-DΔHBx compared to those infected with HBV WT. The infection with HBx-deficient virus only reduced the level of HBx but did not affect the expression of other viral proteins (Figures 3C, D). These data revealed that the expression of DDX17 was enhanced by HBx. We further studied the functional role of DDX17 in HBx expression. As expected, DDX17 overexpression upregulated the expression of HBx, while DDX17 depletion downregulated HBx expression (Figures 3E, F). Concordantly, the expression of other viral proteins is not affected after DDX17 overexpression or deletion (Figures S1A–C). To investigate the potential mechanism underlying DDX17 regulated the expression of HBx, we co-transfected the DDX17 overexpression plasmid with Flag-HBx into HepG2 cells and it treated with actinomycin D to block transcription and measured decay of existing mRNAs by performing time-course real-time PCR. The results revealed that DDX17 could enhance HBx expression by stabilizing the half-life of HBx mRNA, indicating that DDX17 could promote the HBx post-transcriptional by regulating HBx mRNA stability (Figure 3G). Altogether, these results suggests that DDX17 and HBx positively interact.

**Increased DDX17 Expression Induced by HBx Promotes HBV Transcription and Replication**

The above data revealed that DDX17 expression was upregulated by HBx. However, the effect of increased DDX17 expression induced by HBx on HBV was still unclear. To determine whether HBV RNA transcription and DNA replication was also regulated by DDX17, HepG2-NTCP cells were infected with HBV particles before transduction with a plasmid expressing DDX17, and the efficiency was validated by Western blot (Figure 4A). Real-time PCR revealed that the levels of total HBV RNA and 3.5-kb RNA was significantly increased by DDX17 overexpression (Figure 4B). Northern blot analysis also confirmed increased levels of HBV 3.5-, 2.4- and 2.1-kb RNA after DDX17 overexpression (Figure 4C). Furthermore, the levels of HBV DNA replicative intermediates were determined by real-time PCR and Southern blot, both of which revealed that ectopic DDX17 expression markedly increased the levels of HBV DNA replicative intermediates (Figures 4D, E). Taken together, these results demonstrated that overexpression of DDX17 enhanced HBV transcription and replication.
To systematically confirm whether endogenous DDX17 exerts a similar ability in HBV-infected cells, HepG2-NTCP cells were infected with HBV particles before transduction with lentiviruses expressing short hairpin RNAs (shRNAs) targeting DDX17 (shDDX17-1 and shDDX17-2), and the transduction efficacies were validated by Western blot (Figure 4F). In contrast, real-time PCR and Northern blot analysis revealed that the levels of total HBV RNA and 3.5-kb RNA were significantly downregulated in HBV-infected HepG2-NTCP cells expressing shDDX17 (Figures 4G, H). DDX17 suppression also resulted in decreased levels of HBV DNA replicative intermediates (Figures 4I, J). Overall, these results indicate that DDX17 plays a vital role in promoting HBV transcription and replication.

**DDX17 Promotes HBV Transcription and Replication by Upregulating ZWINT**

To better elucidate the potential molecular mechanism by which DDX17 promotes HBV infection, we assessed the differentially expressed genes regulated by DDX17 in HBV-infected HepG2-NTCP cells with or without DDX17 knockdown by using RNA-seq. A log2 FC of 0.585 and an adjusted p value <0.05 were set as the threshold criteria. A total of 2,567 DEGs were identified, including 1,178 upregulated genes and 1,389 downregulated genes (Figure 5A, left panel). The DEGs in liver tissues from HCC patients with and without HBV infection were also analyzed by using RNA-seq, revealing 3,026 DEGs, including 1,745 upregulated genes and 1,281 downregulated genes (Figure 5A, right panel). Then, 181 DEGs were obtained by overlapping the two RNA-seq datasets with the two GEO datasets shown in Figure 1A (GSE83148 and GSE838941) (Figure 5B). Furthermore, the protein interactions between DDX17 and the 181 candidate genes were analyzed by the STRING database, revealing that DDX17 might interact with ZWINT, THBS1, KIF23 and SLA2 (Figure S2A). To determine whether DDX17 physically interacts with the four proteins, we performed a reciprocal coimmunoprecipitation (Co-IP) assay, revealing that DDX17 coprecipitated with ZWINT but not with THBS1, KIF23, or SLA2 (Figures 5C, D). In addition, we further analyzed the effect of DDX17 on the expression level of ZWINT by real-time PCR and Western blot, demonstrating that silencing DDX17 led to a marked reduction in the ZWINT mRNA and protein levels. In contrast, compared with that in control cells, the expression of ZWINT was markedly increased in cells overexpressing DDX17 (Figure 5E; Figure S2B).

**FIGURE 2** | The effect of HBV on DDX17 expression were analyzed in HBV-infected HepG2-NTCP cells. (A, B) HepG2-NTCP cells were infected with HBV (1,000 genome equivalents/cell) and harvested at indicated days. Real time PCR and western blot measured the mRNA and protein level of DDX17, respectively. (C, D) HepG2-NTCP cells were infected with series dose of HBV particle and harvested at 5 days post-infection. Real time PCR and western blot measured the mRNA and protein level of DDX17, respectively. (E) Endogenous DDX17 level in HepG2-NTCP cells which infected with series doses of HBV particles was determined by immunofluorescence staining.
The above data indicates that the expression of ZWINT is regulated by DDX17, and we next sought to determine whether the expression level of ZWINT affects HBV transcription and replication. To do this, we overexpressed ZWINT in HBV-infected HepG2-NTCP cells and real-time PCR showed that ZWINT overexpression markedly increased the levels of total HBV RNAs and 3.5-kb RNA. Moreover, Northern blot analysis suggested that ZWINT increased the levels of 3.5-, 2.4- and 2.1-kb HBV RNA (Figures S2A–C). In addition, real-time PCR and Southern blotting further demonstrated that ectopic ZWINT expression markedly increased the levels of HBV DNA replicative intermediates (Figures S3D, E). ZWINT depletion led to significant decreases in the HBV RNA and DNA levels (Figures 5F–I; Figure S3F), indicating that silencing ZWINT inhibited HBV transcription and replication.

Next, we further confirmed the involvement of ZWINT in the modulation of DDX17-mediated HBV transcription and replication. We first investigated the effect of ZWINT overexpression on DDX17-silenced cells by examining the levels of total HBV RNA, 3.5-kb RNA and HBV DNA. As expected, ZWINT overexpression significantly restored the inhibition of HBV transcription and replication in DDX17 knockdown cells (Figures 5J, K). In short, we revealed that DDX17 facilitated HBV transcription and replication in a ZWINT-dependent manner.
DDX17 Promotes HBV Transcription and Replication In Vivo

Although the inhibitory effect of DDX17 depletion on HBV infection cell models has been demonstrated, its functional implications in vivo are still unknown. To evaluate the functional roles of DDX17 in vivo, we constructed a mouse model of HBV infection utilizing HBV (r) cccDNA using site-specific DNA recombination. Mice from each group were treated with $2E+11$ v. g./mL AAV-shDDX17 or AAV-shCont and then sacrificed on the indicated day post injection for a series of analyses (Figure 6A). Consistent with the in vitro observations, DDX17 depletion markedly inhibited HBV infection. First, the transduction efficiency of the AAV-based viral vector in the mice model in vivo was confirmed by Western blot (Figure S4A).
Meanwhile, DDX17 depletion markedly reduced the serum levels of HBV DNA during treatment, as determined by real-time PCR (Figure 6B). The animals were sacrificed after 20 days of treatment, and liver tissues were collected to evaluate the HBV RNA and HBV DNA levels in the mouse liver. Consistently, real-time PCR confirmed that the levels of intrahepatic HBV DNA, total HBV RNAs and 3.5-kb RNA were significantly reduced after AAV-shDDX17 treatment (Figures 6C–E). In addition, Western blot assays indicated that DDX17 depletion reduced the protein expression of HBc (Figures 6F, G). Compared with those in control mice, DDX17-depleted mice had significantly decreased serum levels of HBsAg as determined by ELISA (Figure 6H). Moreover, no abnormal pathological changes were observed by HE staining in either group (Figure 6I). Next, the expression levels of HBsAg and HbcAg in liver tissue were measured by immunohistochemistry, demonstrating that DDX17 depletion apparently reduced their expression in liver tissue (Figure 6J). Taken together, these results strongly confirmed that DDX17 depletion repressed HBV infection in vivo.
Increased Expression of DDX17 Mediated by HBx Promotes the Metastasis of HBV-Related HCC

To further investigate the functional role of DDX17 in the development of HBV-related HCC mediated by HBx, we co-transfected the DDX17 overexpression plasmid with Flag-HBx into HCC cells (Huh-7 and PLC/PRF/5). Increased cell migration was observed in both cell lines, which indicated that DDX17 facilitated HBx-mediated HCC migration (Figures 7A, B). To better understand the association between the HBx-mediated increase in DDX17 expression and HCC cell migration, shRNAs targeting DDX17 (shDDX17-1 and shDDX17-2) were co-transfected with Flag-HBx into Huh-7 and PLC/PRF/5 cells. Transwell assays confirmed that in
contrast to DDX17 overexpression, the effect of HBx on the migration of Huh-7 and PLC/PRF/5 cells was abolished by DDX17 depletion (Figures 7C, D). Moreover, as DDX17 facilitated HBV transcription and replication in a ZWINT-dependent manner, we co-transfected the shRNAs targeting DDX17 (shDDX17) and ZWINT overexpression plasmid with Flag-HBx into Huh-7 cells to assess the involvement of ZWINT in DDX17-mediated HBV in relation to HCC migration. As expected, the transwell assay confirmed that the inhibition of cell migration induced by the absence of DDX17 was rescued by ZWINT overexpression (Figure 7E). Meanwhile, we co-transfected the DDX17 overexpression plasmid and siRNAs targeting ZWINT (siZWINT) with Flag-HBx into Huh-7 cells and the results show that knockdown of ZWINT resulted in the disappearance of DDX17 promoting effect on cell migration (Figure S5A). In short, we demonstrated that DDX17 facilitated HBx-mediated HCC migration.

DDX17 Expression Is Associated With HBV-Related HCC Metastasis in Clinical Samples

To further confirm the clinical significance of DDX17 expression in HBV-related HCC, we recruited 24 patients diagnosed with HBV-related HCC in this study and divided them into two groups based on their metastatic status (metastatic and nonmetastatic groups). The clinical and virological characteristics of these patients are summarized in Table 1. To investigate the potential role of DDX17 in HBV-related HCC, we detected the DDX17 protein levels by Western blotting, revealing increased protein expression levels of DDX17 in the metastatic group compared to the nonmetastatic group (Figures 8A, B). Concordantly, real-time PCR revealed that compared to the nonmetastatic group, the mRNA level of DDX17 in the metastatic group was upregulated significantly (Figure 8C), which suggests that DDX17 plays a positive role in HBV-
mediated HCC metastasis. Moreover, the correlation between DDX17 and HBV DNA was analyzed and the data showed a significantly positive correlation between the liver DDX17 mRNA levels and serum HBV DNA levels in patients diagnosed with HBV-related HCC (Pearson correlation coefficient $r = 0.6301$, $P = 0.001$; Figure 8D). Collectively, the above results support that DDX17 plays an important role in HBV-mediated HCC metastasis.

**DISCUSSION**

As an important member of the DEAD-box family, DDX17 is involved in various pathological processes, especially HCC metastasis. Xue and colleagues determined that DDX17 altered the migration and invasion abilities of HCC by altering its expression levels in HCC cell lines in vitro (32). Moreover, Chen and colleagues reported that DDX17 regulates the alternative splicing of PXN-AS1 to promote HCC metastasis (20). Given that chronic HBV infection is the major aetiology of HCC, we explored the functional role of DDX17 in HBV-related HCC. We demonstrated that DDX17 is positively related to HBV replication and promotes HBx-mediated HCC metastasis. Our findings are similar to those of the studies mentioned above and provide more evidence for the essential roles of DDX17 in HBV and HCC. Interestingly, in contrast to DDX17, another DEAD-box family member, DDX5, whose structure is similar to that of DDX17, is negatively related to HBV replication and inhibits HBV-related HCC development (33). Similarly, in vitro and in vivo data suggest that DDX5 dramatically inhibits HCC tumorigenesis (34). Collectively, these reports indicate that DEAD-box family members regulate HBV-related HCC in multiple ways and may have opposite effects on tumorigenesis.

As a general activator of gene expression, HBx is widely involved in the development of HBV-related HCC. HBx promotes HCC by upregulating the expression of oncogenes. A previous study showed that HBx activated the transcription of FoxM1 to promote HBx-mediated HCC metastasis, while FoxM1 inhibition significantly decreased HBx-enhanced hepatoma cell invasion in vitro and lung metastasis in vivo (35). Additionally, HBx upregulates MSL2 by activating YAP/FoxA1 signaling, and HBx-elevated MSL2 modulates HBV cccDNA in liver cancer cells, leading to hepatocarcinogenesis (36). The downregulation of tumor suppressor genes is another mechanism by which HBx promotes tumor progression. For instance, HBx was shown to reduce the level of GNA14, which promoted the proliferation and metastasis of HCC (37). In addition, HBx was shown to induce the expression of the miRNA TLRC-m0008_3p (miR-3928v) through the NF-kB/EGR1 signaling pathway, resulting in the downregulation of the tumorsuppressor gene VDAC3 to accelerate the progression of HCC (38). As mentioned above, HBx participates in the development of HCC by regulating gene expression. Consistently, our results showed that HBx enhances the expression of DDX17 to promote the metastasis of HBV-related HCC. We further explored the relationship between DDX17 and HBx and found that DDX17 upregulated the expression of HBx in cells by stimulating the X promoter of HBV but did not affect the expression of exogenous flag-HBx with the CMV promoter, which differs from the X promoter. Therefore, we speculated that the X promoter is the essential site at which DDX17 regulates HBx.

ZWINT is a centromere-complex component required for the mitotic spindle checkpoint and several centromere proteins

| Patient | Age (y) | Gender (F/M) | HBV DNA (IU/ml) | HBsAg (IU/ml) | ALT (IU/ml) | Metastasis (Yes/No) | Differentiation grade |
|---------|---------|--------------|----------------|---------------|-------------|---------------------|----------------------|
| 1       | 76      | F            | 2.56E+06        | 1772          | 64          | Y                   | G1                   |
| 2       | 60      | M            | 7.03E+06        | 2360          | 23          | Y                   | G2                   |
| 3       | 46      | M            | 3.58E+07        | 2254.55       | 29          | Y                   | G4                   |
| 4       | 24      | M            | 2.87E+05        | 37.52         | 50          | Y                   | G2                   |
| 5       | 43      | M            | 5.50E+05        | 1214          | 34          | Y                   | G2                   |
| 6       | 52      | F            | 5.51E+05        | 834.24        | 62          | Y                   | G2                   |
| 7       | 71      | F            | 1.51E+04        | 2040          | 20          | Y                   | G2                   |
| 8       | 50      | M            | 2.87E+06        | 1913.91       | 45          | Y                   | G2                   |
| 9       | 42      | M            | 4.62E+04        | 2486          | 41          | Y                   | G2                   |
| 10      | 62      | F            | 1.57E+06        | 105           | 33          | Y                   | G2                   |
| 11      | 42      | M            | 4.37E+04        | 5740          | 23          | Y                   | G3                   |
| 12      | 61      | M            | 6.26E+04        | 2090          | 37          | Y                   | G2                   |
| 13      | 46      | M            | 7.89E+05        | 20.33         | 33          | N                   | G1                   |
| 14      | 53      | M            | 1.48E+06        | 1587          | 83          | N                   | G1                   |
| 15      | 39      | M            | 6.60E+05        | 3101.42       | 171         | N                   | G4                   |
| 16      | 58      | M            | 2.78E+04        | 1734          | 111         | N                   | G2                   |
| 17      | 40      | M            | 3.52E+06        | 2256          | 82          | N                   | G4                   |
| 18      | 47      | M            | 3.91E+04        | 950           | 50          | N                   | G2                   |
| 19      | 65      | F            | 1.07E+06        | 79.45         | 20          | N                   | G3                   |
| 20      | 63      | M            | 5.35E+05        | 2320          | 42          | N                   | G2                   |
| 21      | 56      | M            | 1.12E+05        | 3208          | 32          | N                   | G3                   |
| 22      | 66      | F            | 5.22E+05        | 845.12        | 32          | N                   | G2                   |
| 23      | 56      | F            | 1.82E+04        | 123           | 26          | N                   | G2                   |
| 24      | 64      | F            | 1.48E+04        | 3445          | 63          | N                   | G1                   |

y, years; F, Female; M, Male; G1, Well differentiated; G2, Moderately differentiated; G3, Poorly differentiated; G4, Undifferentiated.

TABLE 1 | Clinical and virological characteristics of the subjects enrolled in the study.
similar to ZWINT have been proven to be necessary for HCC. Centromere protein A (CENPA) is one of the most important centromere proteins in HCC. When researchers used Jumonji lysine demethylase (JmjC) inhibitors, which strongly depleted the expression of CENPA, \textit{in vitro} and \textit{in vivo}, HCC progression was inhibited (39). Moreover, CENPA may be a therapeutic target for HCC since its knockdown affects HCC cell proliferation (40). Another centromere protein, centromere protein M (CENPM), was shown to be overexpressed in HCC samples, and further studies found that CENPM inhibited cell apoptosis and promoted cell cycle progression by affecting P53 signaling to promote HCC. Researchers also reported that HBx decreased the expression of miR-1270 to upregulate that of CENPM and thereby promote HCC (41). Some studies have proven that the expression of ZWINT may be altered in HCC and that these changes regulate the development of HCC (42, 43). Moreover, ZWINT was determined to be the key gene involved in the molecular pathogenesis of HBV-related HCC by researchers performing an integrative analysis of all available high-throughput gene expression data on HBV-related HCC patients (44). Our study provides further evidence regarding the regulation of HBV and HCC and suggest that ZWINT can serve as a novel therapeutic target for HBV-related HCC.

Generally, our study results suggest that DDX17 plays a key role in promoting the occurrence and development of HBV-related HCC and that inhibition of DDX17 can block tumor metastasis mediated by HBx. This finding indicates that DDX17 is a potential target for the development of mechanism-based HBV-related HCC prevention strategies.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Clinical Research Ethics Committee of the Chongqing Medical University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Laboratory Animal Center of the Chongqing Medical University. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

JC and S-TC designed the study. M-LD, XW, J-HR, H-BY, Y-PQ, ZY, M-LY, C-YZ, HZ, S-TC, and XH performed the experiments and analyses. J-HR, S-TC, and JC provided the materials. M-LD,
REFERENCES

1. Chu PY, Tung SL, Tsai KW, Shen FP, Chan SH. Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. *Cancers* (Basel) 2020) 12(7):1843. doi: 10.3390/cancers12071843

2. Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma With Immunotherapy: A Review of Current and Future Options. *J Clin Transl Hepatol* (2020) 8(2):168–76. doi: 10.14128/JCTH.2020.00001

3. Renzulli M, Brandi N, Argalia G, Brocchi S, Faroldi A, Fantis S, et al. Morphological, Dynamic and Functional Characteristics of Liver Pseudolesions and Benign Lesions. *Radiol Med* (2022) 127(2):129–44. doi: 10.1007/s11547-022-01449-w

4. Seo W, Gao Y, He Y, Sun J, Xu H, Feng D, et al. ALDH2 Deficiency Promotes Alcohol-Associated Liver Cancer by Activating Oncogenic Pathways via Oxidized DNA-Enriched Extracellular Vesicles. *J Hepatol* (2019) 71(5):1000–11. doi: 10.1016/j.jhep.2019.06.018

5. Stichel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, et al. Genetic Variation in HSD17B13 Increases the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. *Hepatology* (2020) 72(1):88–102. doi: 10.1002/hep.30996

6. Alvarez EG, Demeulemeester J, Otero P, Jolly C, Garcia-Souto D, Pequeno-Valtierra A, et al. Aberrant Integration of Hepatitis B Virus DNA Promotes Major Restructuring of Human Hepatocellular Carcinoma Genome Architecture. *Nat Commun* (2021) 12(1):6910. doi: 10.1038/s41467-021-26805-8

7. Chen Y, Li L, Lan J, Cui Y, Rao X, Zhao J, et al. CRISPR Screens Uncover Major Restructuring of Human Hepatocellular Carcinoma Genome Architecture. *Nat Commun* (2021) 12(1):6910. doi: 10.1038/s41467-021-26805-8

8. Gu F, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, et al. Intra-Arterial Idarubicin_Lipiodol Without Embolisation in Hepatocellular Carcinoma: The LIDA-B Phase I Trial. *J Hepatol* (2018) 68(6):1163–71. doi: 10.1016/j.jhep.2018.01.022

9. Linder P, Jankowsky E. From Unwinding to Clamping - The DEAD Box RNA Helicase Family. *Nat Rev Mol Cell Biol* (2011) 12(8):505–16. doi: 10.1038/nrm3154

10. Fuller-Pace FV. DEAD Box RNA Helicase Functions in Cancer. *RNA Biol* (2013) 10(1):121–32. doi: 10.4161/rna.23312

11. de Silva D, Poliquin S, Zeng R, Zamudio-Ochoa A, Marrero N, Perez-Martinez X, et al. The DEAD-Box Helicase Msx116 Plays Distinct Roles in Mitochondrial Ribogenesis and mRNA-Specific Translation. *Nucleic Acids Res* (2017) 45(11):6628–43. doi: 10.1093/nar/gkx426

12. Kao SH, Cheng WC, Wang YT, Wu HT, Yeh HY, Chen YJ, et al. Regulation of miRNA Biogenesis and Histone Modification by K63-Polyubiquitinated DDX17 Controls Cancer Stem-Like Features. *Cancer Res* (2019) 79(10):2549–63. doi: 10.1158/0008-5472.CAN-18-2376

13. Wu KJ. The Role of miRNA Biogenesis and DDX17 in Tumorigenesis and Cancer Stemness. *BioMed J* (2020) 43(2):107–14. doi: 10.1016/j.bmj.2020.03.001

14. Long T, Abbasni H, Hernandez JE, Li Y, Sayed IM, Ma S, et al. RNA Binding Protein DDX5 Directs Tuft Cell Specification and Function to Regulate Microbial Repertoire and Disease Susceptibility in the Intestine. *Gut* (2021). doi: 10.1136/gutjnl-2021-324984

15. Mo J, Liang H, Su C, Li P, Chen J, Zhang B, DDX3X: Structure, Physiological Functions and Cancer. *Mol Cancer* (2021) 20(1):38. doi: 10.1186/s12943-021-01325-7

16. Pan L, Huang X, Liu ZX, Ye Y, Li R, Zhang J, et al. Inflammatory Cytokine-Regulated tRNA-Derived Fragment TRF2-1 Suppresses Pancreatic Ductal Adenocarcinoma Progression. *J Clin Invest* (2021) 131(22):e148130. doi: 10.1172/JCI148130

17. Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, et al. Global Analysis of Metastasis-Associated Gene Expression in Primary Cultures From Clinical Specimens of Clear-Cell Renal-Cell Carcinoma. *Int J Cancer* (2018) 123(5):1080–9. doi: 10.1002/ijc.25637

18. Zhou HZ, Li F, Cheng ST, Yu X, Deng HJ, Gu DY, et al. DDX17-Regulated Alternative Splicing That Produced an Oncogenic Isoform of PXN-AS1 to Promote HCC Metastasis. *Hepatology* (2021) 75(4):847–65. doi: 10.1002/hep.32195

19. Bortz E, Westera L, Maarmay J, Steel J, Albrecht RA, Manicassamy B, et al. Host- and Strain-Specific Regulation of Influenza Virus Polymerase Activity by Interacting Cellular Proteins. *mBio* (2011) 2(4):e00151-11. doi: 10.1128/mBio.00151-11

20. Li G, Deng T, Pan W, Shi X, Dai J, DEAD-Box RNA Helicase DDX3X Inhibits DENVir Replication via Regulating Type One Interferon Pathway. *Biochem Biophys Res Commun* (2015) 456(1):327–32. doi: 10.1016/j.bbrc.2014.11.080

21. Kukhanova MK, Karpenko IL, Ivanov AV. DEAD-Box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs. *Molcules* (2020) 25(4):1015. doi: 10.3390/molecules25041015

22. Nelson CR, Mrozowich T, Park SM, D’Souza S, Henrickson A, Vigar JR, et al. Human DDX17 Unwinds Rift Valley Fever Virus Non-Coding RNAs. *Int J Mol Sci* (2020) 22(1):54. doi: 10.3390/ijms22010054

23. Liu XY, Tang SH, Wu SL, Luo YH, Cao MR, Zhou HK, et al. Epigenetic Modulation of Insulin-Like Growth Factor-II Overexpression by Hepatitis B Virus X Protein in Hepatocellular Carcinoma. *Am J Canc Res* (2015) 5(3):956–78.

24. Leverro M, Zucman-Rossi J. Mechanisms of HBV-Induced Hepatocellular Carcinoma. *J Hepatol* (2016) 64(1):Suppl5-S84-S101. doi: 10.1016/j.jhep.2016.02.021

25. Gamberi T, Magherini F, Modesti A, Fiaschi T. Adiponectin Signaling Pathways in Liver Diseases. *Biomedicines* (2018) 6(2):52. doi: 10.3390/biomedicines6020052

26. Xue J, Cao Z, Cheng Y, Wang J, Liu Y, Yang R, et al. Acetylation of Alpha-Fetoprotein Promotes Hepatocellular Carcinoma Progression. *Cancer Lett* (2020) 471:12–26. doi: 10.1016/j.canlet.2019.11.043

27. Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, Paturel A, et al. Hepatitis B Protein HBx Binds the DLEU2 lncRNA to Sustain cccDNA and Host Cancer-Related Gene Transcription. *Gut* (2020) 69(11):2016–24. doi: 10.1136/gutjnl-2019-319637
30. Wang P, Guo QS, Wang ZW, Qian HX. HBx Induces HepG-2 Cells Autophagy Through PI3K/Akt-mTOR Pathway. *Mol Cell Biochem* (2013) 372(1-2):1-8. doi: 10.1007/s11010-012-1457-x

31. Ching RHH, Sze KMF, Lau EYT, Chiu YT, Lee JMF, Ng IOL, et al. C-Terminal Truncated Hepatitis B Virus X Protein Regulates Tumourigenicity, Self-Renewal, and Chemoresistance via STAT3/Nanog Signalling Pathway: Abridged Secondary Publication. *Hong Kong Med J* (2020) 26 (Suppl 4) (3):22-5.

32. Xue Y, Jia X, Li C, Zhang K, Li L, Wu J, et al. DDX17 Promotes Hepatocellular Carcinoma Progression via Inhibiting Klf4 Transcriptional Activity. *Cell Death Dis* (2019) 10(11):814. doi: 10.1038/s41419-019-2044-9

33. Mani SKK, Yan B, Cui Z, Sun J, Utturkar S, Foca A, et al. Restoration of RNA Helicase DDX5 Suppresses Hepatitis B Virus (HBV) Biosynthesis and Wnt Signaling in HBV-Related Hepatocellular Carcinoma. *Theranostics* (2020) 10 (24):10957-72. doi: 10.7150/thno.49629

34. Zhang H, Zhang Y, Zhu X, Chen C, Zhang C, Xia Y, et al. DEAD Box Protein 5 Inhibits Liver Tumorigenesis by Stimulating Autophagy via Interaction With P62/Sqstm1. *Hepatology* (2019) 69(3):1046-63. doi: 10.1002/hep.30300

35. Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, et al. Upregulated FoxM1 Expression Induced by Hepatitis B Virus X Protein Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatitis B Virus-Related Hepatocellular Carcinoma. *J Hepatol* (2012) 57(3):600-12. doi: 10.1016/j.jhep.2012.04.020

36. Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, et al. Hepatitis B Virus X Protein-Elevated MSL2 Modulates Hepatitis B Virus Covalently Closed Circular DNA by Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis. *Hepatology* (2017) 66(5):1413-29. doi: 10.1002/hep.29316

37. Song G, Zhu X, Xuan Z, Zhao L, Dong H, Chen J, et al. Hypermethylation of GNA14 and Its Tumor-Suppressive Role in Hepatitis B Virus-Related Hepatocellular Carcinoma. *Theranostics* (2021) 11(5):2318-33. doi: 10.7150/thno.48739

38. Zhang Q, Song G, Yao L, Liu Y, Liu M, Li S, et al. miR-3928v Is Induced by HBx via NF-Kappab/EGFR1 and Contributes to Hepatocellular Carcinoma Malignancy by Down-Regulating Vdac3. *J Exp Clin Canc Res* (2018) 37(1):14. doi: 10.1186/s13046-018-0681-y

39. Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, et al. A Comprehensive Study of Epigenetic Alterations in Hepatocellular Carcinoma Identifies Potential Therapeutic Targets. *J Hepatol* (2019) 71(1):78-90. doi: 10.1016/j.jhep.2019.03.007

40. Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, et al. ShRNA-Targeted Centromere Protein A Inhibits Hepatocellular Carcinoma Growth. *PLoS One* (2011) 6(3): e17794. doi: 10.1371/journal.pone.0017794

41. Xiao Y, Najeem RM, Ma D, Yang K, Zhong Q, Liu Q. Upregulation of CENPM Promotes Hepatocarcinogenesis Through MutipleMechanisms. *J Exp Clin Canc Res* (2019) 38(1):458. doi: 10.1186/s13046-019-1444-0

42. Ying H, Xu Z, Chen M, Zhou S, Liang X, Cai X. Overexpression of Zwt Predicts Poor Prognosis and Promotes the Proliferation of Hepatocellular Carcinoma by Regulating Cell-Cycle-Related Proteins. *Onco Targets Ther* (2018) 11:689-702. doi: 10.2147/OTT.S152138

43. Zhang G, Kang Z, Mei H, Huang Z, Li H. Promising Diagnostic and Prognostic Value of Six Genes in Human Hepatocellular Carcinoma. *Am J Transl Res* (2020) 12(4):1239-54.

44. Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. *BioMed Res Int* (2020) 2020:7653506. doi: 10.1155/2020/7653506

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Dong, Wen, He, Ren, Yu, Qin, Yang, Zhang, Zhou, Zhang, Cheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practise. No use, distribution or reproduction is permitted which does not comply with these terms.